## => d his

(FILE 'HOME' ENTERED AT 08:05:13 ON 15 AUG 2003) FILE 'MEDLINE, BIOSIS, CAPLUS' ENTERED AT 08:06:45 ON 15 AUG 2003 T.1 21701 S PURIF? (3A) DNA L225 S L1 (9A) (RNA OR RNASE) (3A) FREE L318 DUP REM L2 (7 DUPLICATES REMOVED) L<sub>4</sub> 781 S CESIUM (9A) DNA L5 2 S L4 (9A) PURITY L6 52 S CSCL (9A) PURITY 28 S L6 AND (DNA OR NUCLEIC OR PLASMID) L7 18 DUP REM L7 (10 DUPLICATES REMOVED) T.8 FILE 'STNGUIDE' ENTERED AT 08:11:06 ON 15 AUG 2003 FILE 'MEDLINE, CAPLUS' ENTERED AT 08:20:13 ON 15 AUG 2003 L9 0 S RNASE (9A) CESIUM (9A) PLASMID L10 10 S RNASE (9A) CESIUM L11 18 S ENDOTOXIN AND (CESIUM OR CSCL) T.12 17 DUP REM L11 (1 DUPLICATE REMOVED) FILE 'STNGUIDE' ENTERED AT 08:27:46 ON 15 AUG 2003 FILE 'MEDLINE' ENTERED AT 08:37:59 ON 15 AUG 2003 L13 93 S PUR? (9A) (CESIUM OR CSCL) (9A) (DNA OR PLASMID OR NUCLEIC) 93 DUP REM L13 (0 DUPLICATES REMOVED) L14L150 S (MANGANESE (W) CHLORIDE OR MNCL#) AND (CESIUM OR CSCL) (5A) ( 0 S (MANGANESE (W) CHLORIDE OR MNCL#) AND (CESIUM OR CSCL#) (5A) L16 590 S TRANSFECTION AND (SPERMINE OR SPERMIDINE OR NETROPSIN OR DIST 1.17 L18 3 S L17 AND CESIUM 0 S L17 AND CSCL# L20 143 S L17 AND PY<1995 L21447 S L17 NOT L20 FILE 'STNGUIDE' ENTERED AT 08:58:54 ON 15 AUG 2003 FILE 'MEDLINE' ENTERED AT 08:59:29 ON 15 AUG 2003 FILE 'STNGUIDE' ENTERED AT 08:59:29 ON 15 AUG 2003 FILE 'MEDLINE' ENTERED AT 09:02:43 ON 15 AUG 2003 FILE 'STNGUIDE' ENTERED AT 09:02:43 ON 15 AUG 2003 FILE 'MEDLINE' ENTERED AT 09:06:25 ON 15 AUG 2003 FILE 'STNGUIDE' ENTERED AT 09:06:25 ON 15 AUG 2003 FILE 'MEDLINE' ENTERED AT 09:07:54 ON 15 AUG 2003 FILE 'STNGUIDE' ENTERED AT 09:07:54 ON 15 AUG 2003 FILE 'MEDLINE' ENTERED AT 09:08:19 ON 15 AUG 2003 FILE 'STNGUIDE' ENTERED AT 09:09:10 ON 15 AUG 2003 FILE 'MEDLINE' ENTERED AT 09:10:54 ON 15 AUG 2003 FILE 'STNGUIDE' ENTERED AT 09:10:54 ON 15 AUG 2003

ENTRY . SESSION FULL ESTIMATED COST 0.12 92.49 DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL ENTRY SESSION CA SUBSCRIBER PRICE 0.00 -2.60 FILE 'MEDLINE' ENTERED AT 09:12:01 ON 15 AUG 2003 FILE LAST UPDATED: 14 AUG 2003 (20030814/UP). FILE COVERS 1958 TO DATE. On April 13, 2003, MEDLINE was reloaded. See HELP RLOAD for details. MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2003 vocabulary. See http://www.nlm.nih.gov/mesh/changes2003.html for a description on changes. This file contains CAS Registry Numbers for easy and accurate substance identification. => d his (FILE 'HOME' ENTERED AT 08:05:13 ON 15 AUG 2003) FILE 'MEDLINE, BIOSIS, CAPLUS' ENTERED AT 08:06:45 ON 15 AUG 2003 L121701 S PURIF? (3A) DNA 25 S L1 (9A) (RNA OR RNASE) (3A) FREE L2L3 18 DUP REM L2 (7 DUPLICATES REMOVED) 781 S CESIUM (9A) DNA T.4 L5 2 S L4 (9A) PURITY 52 S CSCL (9A) PURITY L6 L7 28 S L6 AND (DNA OR NUCLEIC OR PLASMID) L8 18 DUP REM L7 (10 DUPLICATES REMOVED) FILE 'STNGUIDE' ENTERED AT 08:11:06 ON 15 AUG 2003 FILE 'MEDLINE, CAPLUS' ENTERED AT 08:20:13 ON 15 AUG 2003 L9 0 S RNASE (9A) CESIUM (9A) PLASMID L10 10 S RNASE (9A) CESIUM 18 S ENDOTOXIN AND (CESIUM OR CSCL) L11L1217 DUP REM L11 (1 DUPLICATE REMOVED) FILE 'STNGUIDE' ENTERED AT 08:27:46 ON 15 AUG 2003 FILE 'MEDLINE' ENTERED AT 08:37:59 ON 15 AUG 2003 93 S PUR? (9A) (CESIUM OR CSCL) (9A) (DNA OR PLASMID OR NUCLEIC) L13L1493 DUP REM L13 (0 DUPLICATES REMOVED) L15 0 S (MANGANESE (W) CHLORIDE OR MNCL#) AND (CESIUM OR CSCL) (5A) ( L16 0 S (MANGANESE (W) CHLORIDE OR MNCL#) AND (CESIUM OR CSCL#) (5A) 590 S TRANSFECTION AND (SPERMINE OR SPERMIDINE OR NETROPSIN OR DIST

FILE 'STNGUIDE' ENTERED AT 08:58:54 ON 15 AUG 2003

3 S L17 AND CESIUM

0 S L17 AND CSCL#

143 S L17 AND PY<1995

447 S L17 NOT L20

L17

L18 L19

L20

L21

FILE 'MEDLINE' ENTERED AT 08:59:29 ON 15 AUG 2003

FILE 'STNGUIDE' ENTERED AT 08:59:29 ON 15 AUG 2003

FILE 'MEDLINE' ENTERED AT 09:02:43 ON 15 AUG 2003

FILE 'STNGUIDE' ENTERED AT 09:02:43 ON 15 AUG 2003

FILE 'MEDLINE' ENTERED AT 09:06:25 ON 15 AUG 2003

FILE 'STNGUIDE' ENTERED AT 09:06:25 ON 15 AUG 2003

FILE 'MEDLINE' ENTERED AT 09:07:54 ON 15 AUG 2003

FILE 'STNGUIDE' ENTERED AT 09:07:54 ON 15 AUG 2003

FILE 'MEDLINE' ENTERED AT 09:08:19 ON 15 AUG 2003

FILE 'STNGUIDE' ENTERED AT 09:09:10 ON 15 AUG 2003

FILE 'MEDLINE' ENTERED AT 09:10:54 ON 15 AUG 2003

FILE 'STNGUIDE' ENTERED AT 09:10:54 ON 15 AUG 2003

FILE 'MEDLINE' ENTERED AT 09:12:01 ON 15 AUG 2003

=> s 17 and influenza

375986 17

34822 INFLUENZA

L22 667 17 AND INFLUENZA

=> s 117 and influenza

34822 INFLUENZA

L23 14 L17 AND INFLUENZA

=> d 1-14 ti

- L23 ANSWER 1 OF 14 MEDLINE on STN
- TI Efficient gene delivery to primary neuron cultures using a synthetic peptide vector system.
- L23 ANSWER 2 OF 14 MEDLINE on STN
- TI A powerful cooperative interaction between a fusogenic peptide and lipofectamine for the enhancement of receptor-targeted, non-viral gene delivery via integrin receptors.
- L23 ANSWER 3 OF 14 MEDLINE on STN
- TI The Leishmania ATP-binding cassette protein PGPA is an intracellular metal-thiol transporter ATPase.
- L23 ANSWER 4 OF 14 MEDLINE on STN
- TI Efficient gene delivery to vascular smooth muscle cells using a nontoxic, synthetic peptide vector system targeted to membrane integrins: a first step toward the gene therapy of chronic rejection.
- L23 ANSWER 5 OF 14 MEDLINE on STN
- TI Chloroquine and amphipathic peptide helices show synergistic transfection in vitro.
- L23 ANSWER 6 OF 14 MEDLINE on STN
- TI Membrane permeabilization and efficient gene transfer by a peptide containing several histidines.
- L23 ANSWER 7 OF 14 MEDLINE on STN
- TI Efficient gene transfer into mammalian cells with cholesterylspermidine.
- L23 ANSWER 8 OF 14 MEDLINE on STN
- TI Delivery of DNA into mammalian cells by receptor-mediated endocytosis and

gene therapy.

- L23 ANSWER 9 OF 14 MEDLINE on STN
- TI Ribozyme mediated destruction of **influenza** A virus in vitro and in vivo.
- L23 ANSWER 10 OF 14 MEDLINE on STN
- TI The influence of endosome-disruptive peptides on gene transfer using synthetic virus-like gene transfer systems.
- L23 ANSWER 11 OF 14 MEDLINE on STN
- TI Specific gene transfer mediated by lactosylated poly-L-lysine into hepatoma cells.
- L23 ANSWER 12 OF 14 MEDLINE on STN
- TI Gene transfer into hepatocytes using asialoglycoprotein receptor mediated endocytosis of DNA complexed with an artificial tetra-antennary galactose ligand.
- L23 ANSWER 13 OF 14 MEDLINE on STN
- TI Influenza virus hemagglutinin HA-2 N-terminal fusogenic peptides augment gene transfer by transferrin-polylysine-DNA complexes: toward a synthetic virus-like gene-transfer vehicle.
- L23 ANSWER 14 OF 14 MEDLINE on STN
- TI Transfer of condensed viral DNA into eukaryotic cells using proteoliposomes.

## => d 7 bib ab

- L23 ANSWER 7 OF 14 MEDLINE on STN
- AN 96220162 MEDLINE
- DN 96220162 PubMed ID: 8660349
- TI Efficient gene transfer into mammalian cells with cholesteryl-spermidine.
- AU Moradpour D; Schauer J I; Zurawski V R Jr; Wands J R; Boutin R H
- CS Molecular Hepatology Laboratory, Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, USA.
- NC AA-02666 (NIAAA) AA-08169 (NIAAA) CA-35711 (NCI)
- SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (1996 Apr 5) 221 (1) 82-8.
  - Journal code: 0372516. ISSN: 0006-291X.
- CY United States
- DT Journal; Article; (JOURNAL ARTICLE)
- LA English
- FS Priority Journals
- EM 199607
- ED Entered STN: 19960808 Last Updated on STN: 19960808 Entered Medline: 19960729
- AB The naturally occurring polyamine **spermidine** was covalently conjugated with cholesterol, resulting in a novel cationic compound that mediates efficient gene transfer into mammalian cells. Using reporter plasmids coding for firefly luciferase and beta-galactosidase, a simple procedure was developed allowing highly reproducible and efficient transient and stable **transfection** of HuH-7 cells.

Transfection efficiency could be further increased when a fusogenic peptide derived from the influenza virus hemagglutinin HA2 aminoterminal sequence was included in the cholesteryl-spermidine-DNA complex. Cholesteryl-spermidine

(Transfectall) represents a novel cationic compound for efficient transfection of cultured cells in vitro and has the potential to be used for gene transfer in vivo.

=> s 117 and vaccine# 108258 VACCINE# L24 4 L17 AND VACCINE#

=> d 1-4 ti

L24 ANSWER 1 OF 4 MEDLINE on STN

TI A study of systems for delivering antigens and plasmid DNA for intranasal immunization against tick-borne encephalitis virus.

L24 ANSWER 2 OF 4 MEDLINE on STN

TI Poly-L-lysine-based molecular conjugate vectors: a high efficiency gene transfer system for human progenitor and leukemia cells.

L24 ANSWER 3 OF 4 MEDLINE on STN

TI Large-scale feasibility of gene transduction into human CD34+ cell-derived dendritic cells by adenoviral/polycation complex.

L24 ANSWER 4 OF 4 MEDLINE on STN

TI Adenovirus-enhanced receptor-mediated transferrinfection for the generation of tumor vaccines.

=> s influenza (4a) DNA (4a) vaccine#

34822 INFLUENZA

704198 DNA

108258 VACCINE#

L25 39 INFLUENZA (4A) DNA (4A) VACCINE#

=> d 1-39 ti

- L26 ANSWER 19 OF 21 MEDLINE on STN
- AN 97414204 MEDLINE
- DN 97414204 PubMed ID: 9269061
- TI Immunogenicity and efficacy of baculovirus-expressed and DNA -based equine influenza virus hemagglutinin vaccines in mice.
- AU Olsen C W; McGregor M W; Dybdahl-Sissoko N; Schram B R; Nelson K M; Lunn D P; Macklin M D; Swain W F; Hinshaw V S
- CS Department of Pathobiological Science, School of Veterinary Medicine, University of Wisconsin-Madison 53706, USA.
- SO VACCINE, (1997 Jul) 15 (10) 1149-56. Journal code: 8406899. ISSN: 0264-410X.
- CY ENGLAND: United Kingdom
- DT Journal; Article; (JOURNAL ARTICLE)
- LA English
- FS Priority Journals
- OS GENBANK-U58195
- EM 199710
- ED Entered STN: 19971105 Last Updated on STN: 19971105 Entered Medline: 19971020
- AB Two fundamentally different approaches to vaccination of BALB/c mice with the hemagglutinin (HA) of A/Equine/Kentucky/1/81 (H3N8) (Eq/KY) were evaluated, that is, administration of HA protein vs administration of HA-encoding DNA. Each vaccine was tested for its immunogenicity and ability to provide protection from homologous virus challenge. HA protein was synthesized in vitro by infection of Sf21 insect cells with a recombinant baculovirus. Intranasal administration of this vaccine induced virus-specific antibodies, as measured by enzyme-linked immunosorbent assay (ELISA), but did not induce virus neutralizing (VN) antibodies. This route of administration provided partial protection from virus challenge, but interestingly, this protection was completely abrogated, rather than enhanced, by co-administration of 10 micrograms of cholera holotoxin. As a second approach, mice were directly vaccinated in vivo by Accell gene gun delivery of plasmid DNA encoding the Eq/KY HA gene. This approach induced VN antibodies as well as virus-specific ELISA antibodies. When two doses of DNA vaccine were administered 3 weeks apart, mice were not protected from challenge, although they cleared the infection more rapidly than control mice. However, when the second DNA vaccination was delayed until 9 weeks after the first, 9 out of 10 vaccinated mice were completely protected. results indicate that the time between initial and booster DNA vaccinations may be an important variable in determining DNA vaccination efficacy.
- L26 ANSWER 20 OF 21 MEDLINE on STN
- AN 96071507 MEDLINE
- DN 96071507 PubMed ID: 7585127
- TI Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus.
- CM Comment in: Nat Med. 1995 Jun;1(6):521-2
- AU Donnelly J J; Friedman A; Martinez D; Montgomery D L; Shiver J W; Motzel S L; Ulmer J B; Liu M A
- CS Department of Virus and Cell Biology, Merck Research Laboratories, West Point, Pennsylvania 19486, USA.
- SO NATURE MEDICINE, (1995 Jun) 1 (6) 583-7. Journal code: 9502015. ISSN: 1078-8956.
- CY United States
- DT Journal; Article; (JOURNAL ARTICLE)
- LA English
- FS Priority Journals
- EM 199512

```
ANSWER 340 OF 447
                      MEDLINE on STN
AN
     1998010146
                    MEDIINE
                PubMed ID: 9349433
DN
     98010146
TI
     Protamine sulfate enhances lipid-mediated gene transfer.
ΑU
     Sorgi F L; Bhattacharya S; Huang L
     Department of Pharmacology, University of Pittsburgh School of Medicine,
CS
     PA 15261, USA.
NC
     CA 59327 (NCI)
     CA 64654 (NCI)
     CA 71731 (NCI)
     GENE THERAPY, (1997 Sep) 4 (9) 961-8.
SO
     Journal code: 9421525. ISSN: 0969-7128.
CY
     ENGLAND: United Kingdom
DT
     Journal; Article; (JOURNAL ARTICLE)
LΑ
     English
FS
     Priority Journals
EM
     199711
     Entered STN: 19971224
     Last Updated on STN: 19971224
     Entered Medline: 19971120
     A polycationic peptide, protamine sulfate, USP, has been shown
AB
     to be able to condense plasmid DNA efficiently for delivery into several
     different types of cells in vitro by several different types of cationic
     liposomes. The monovalent cationic liposomal formulations (DC-Chol and
     lipofectin) exhibited increased transfection activities
     comparable to that seen with the multivalent cationic liposome
     formulation, lipofectamine. This suggests that lipofectamine's superior
     in vitro activity arises from its ability to condense DNA efficiently and
     that protamine's primary role is that of a condensation agent,
     although it also possesses several amino acid sequences resembling that of
     a nuclear localization signal. While the use of polycations to condense
     DNA has been previously reported, the of protamine sulfate, USP
     as a condensation agent was found to be superior to poly-L-lysine as well
     as to various other types of protamine. These differences among
     various salt forms of protamine appear to be attributable to
     structural differences between the protamines and not due to
     differences in the net charge of the molecule. The appearance of lysine
     residues within the protamine molecule correlate with a
     reduction in binding affinity to plasmid DNA as well as an observed loss
     in transfection enhancing activity. This finding sheds light on
     the structural requirements of condensation agents for use in gene
     transfer protocols. Furthermore, protamine sulfate, USP is an
     FDA-approved compound with a documented safety profile and could be
     readily used as an adjuvant to a human gene therapy protocol.
```

CS XX .

- ED Entered STN: 19960124 Last Updated on STN: 19960124 Entered Medline: 19951226
- Vaccination with plasmid DNA expression vectors encoding foreign proteins elicits antibodies and cell-mediated immunity and protects against disease in animal models. We report a comparison of DNA vaccines, using contemporary human strains of virus, and clinically licensed (inactivated virus or subvirion) vaccines in preclinical animal models, to better predict their efficacy in humans. Influenza DNA vaccines elicited antibodies in both non-human primates and ferrets and protected ferrets against challenge with an antigenically distinct epidemic human influenza virus more effectively than the contemporary clinically licensed vaccine. These studies demonstrate that DNA vaccines may be more effective, particularly against different strains of virus, than inactivated virus or subvirion vaccines.
- L26 ANSWER 21 OF 21 MEDLINE on STN
- AN 95185103 MEDLINE
- DN 95185103 PubMed ID: 7879412
- TI Protection of ferrets against influenza challenge with a DNA vaccine to the haemagglutinin.
- AU Webster R G; Fynan E F; Santoro J C; Robinson H
- CS Department of Virology and Molecular Biology, St Jude Children's Research Hospital, Memphis TN 38101-0318.

  NC AI-08831 (NIAID)
- NC AI-08831 (NIAID) AI-34946 (NIAID) CA-21765 (NCI)
- SO VACCINE, (1994 Dec) 12 (16) 1495-8.

  Journal code: 8406899. ISSN: 0264-410X.
- CY ENGLAND: United Kingdom
- DT Journal; Article; (JOURNAL ARTICLE)
- LA English
- FS Priority Journals
- EM 199504
- ED Entered STN: 19950419 Last Updated on STN: 19950419 Entered Medline: 19950406
- AB Immunization of ferrets with a plasmid DNA expressing influenza virus haemagglutinin (pCMV/H1 DNA) provided complete protection from challenge with the homologous A/PR/8/34 (H1N1) influenza virus. Delivery of DNA-coated gold beads by gene gun to the epidermis was much more efficient than intramuscular delivery of DNA in aqueous solution. The antibody response induced by DNA delivered by gene gun was more cross-reactive than DNA delivered in aqueous solution or after natural infection. This novel approach to vaccination against influenza may afford broader protection against antigenic drift than that provided by natural infection.

L21 ANSWER 399 OF 447 MEDLINE on STN

AN 96220162 MEDLINE

DN 96220162 PubMed ID: 8660349

- TI Efficient gene transfer into mammalian cells with cholesterylspermidine.
- AU Moradpour D; Schauer J I; Zurawski V R Jr; Wands J R; Boutin R H
- CS Molecular Hepatology Laboratory, Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, USA.
- NC AA-02666 (NIAAA) AA-08169 (NIAAA) CA-35711 (NCI)
- SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (1996 Apr 5) 221 (1) 82-8.

Journal code: 0372516. ISSN: 0006-291X.

- CY United States
- DT Journal; Article; (JOURNAL ARTICLE)
- LA English
- FS Priority Journals
- EM 199607
- ED Entered STN: 19960808 Last Updated on STN: 19960808 Entered Medline: 19960729
- The naturally occurring polyamine spermidine was covalently conjugated with cholesterol, resulting in a novel cationic compound that mediates efficient gene transfer into mammalian cells. Using reporter plasmids coding for firefly luciferase and beta-galactosidase, a simple procedure was developed allowing highly reproducible and efficient transient and stable transfection of HuH-7 cells.

  Transfection efficiency could be further increased when a fusogenic peptide derived from the influenza virus hemagglutinin HA2 aminoterminal sequence was included in the cholesteryl-spermidine

  -DNA complex. Cholesteryl-spermidine (Transfectall) represents

a novel cationic compound for efficient **transfection** of cultured cells in vitro and has the potential to be used for gene transfer in vivo.

Mary